Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SCOPE2 - A Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients With Oesophageal Cancer Treated With Definitive Chemo-radiation With an Embedded Phase II Trial for Patients With a Poor Early Response Using Positron Emission Tomography (PET)

NCT02741856 is registered in ClinicalTrials.gov with Lisette Nixon as lead sponsor.

NCT NCT02741856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02741856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SCOPE2 - A Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients With Oesophageal Cancer Treated With Definitive Chemo-radiation With an Embedded Phase II Trial for Patients With a Poor Early Response Using Positron Emission Tomography (PET)
Lead sponsor
Lisette Nixon
Phase
Phase 2/3
Overall status
Unknown status
Start date
November 4, 2016
Completion date
April 30, 2023
Enrollment
584 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

oesophageal cancer